Key result
Doxorubicin treatment in bone tumor survivors was associated with significantly reduced heart rate variability at 14.1 years, despite no progression of ECG or echocardiographic abnormalities.
Why the study?
Does historical treatment with doxorubicin cause progressive late cardiac toxicity in bone tumor survivors up to 19 years after treatment?
Cohort (n=29)
Does historical treatment with doxorubicin cause progressive late cardiac toxicity in bone tumor survivors up to 19 years after treatment?
In long-term bone tumor survivors treated with doxorubicin, echocardiographic abnormalities did not progress over time, but heart rate variability significantly declined, suggesting it may be a sensitive marker for late cardiotoxicity.
Answers are grounded in this paper and cite their sources.
HRV may flag late doxorubicin cardiotoxicity missed by standard tests in survivors; leaves open its prognostic value and need for intervention.
BACKGROUND: Longitudinal assessment of cardiac toxicity in anthracycline-treated long-term bone tumor survivors. PROCEDURES: Cardiac status was assessed in 29 patients 14.1 (range 7-18.7) years after treatment with doxorubicin (DOXO) 360 mg/m(2) (median 225-550). The median age of the patients at the time of the study was 32.5 years (range 19.7-52). The evaluation consisted of an electrocardiogram (ECG), 24-hr ambulatory ECG with analysis of heart rate variability (HRV) and echocardiography. The results were compared to those of a study of the same patients that was performed 5 years earlier 8.9 years (range 2.3-14.1) after treatment. [Postma et al.: Med Pediatr Oncol 26:230-237, 1996] RESULTS: We found no progression of ECG abnormalities, arrhythmias, or echocardiographic abnormalities. Females were at risk for reduced contractility (P = 0.006). HRV was significantly reduced compared to age- and sex-matched controls and compared to the previous results. CONCLUSIONS: Anthracycline-related late echocardiographic abnormalities and arrhythmias detected 8.9 years after treatment, showed no further deterioration with ongoing follow-up. However, there was a significant reduction of HRV. This suggests that HRV might be a sensitive test for detection of anthracycline-induced cardiac toxicity.
No takes yet. Share an insight, caveat, or question.
Postma et al. (2002) conducted a cohort in Bone tumor survivors (n=29). Doxorubicin vs. Age- and sex-matched controls and previous results was evaluated on Cardiac status (ECG, 24-hr ambulatory ECG with HRV, and echocardiography). Doxorubicin treatment in bone tumor survivors was associated with significantly reduced heart rate variability at 14.1 years, despite no progression of ECG or echocardiographic abnormalities.
Synapse has enriched 10 related papers. Consider them for comparative context: